NCT06940336

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

A Single Arm, Multicenter, Open-label,Phase IV Clinical Study to Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients withTransthyretin Amyloid Polyneuropathy

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

Conditions

• Transthyretin Amyloid Polyneuropathy

Interventions

Type	Name	Description
DRUG	Tafamidis Meglumine Soft Capsules	20 mg orally once daily for 72 weeks

Timeline

• Start date: 2025-06-19
• Primary completion: 2028-01-01
• Completion: 2028-02-01
• First posted: 2025-04-23
• Last updated: 2025-07-30

Locations

1 site across 1 country: China